Abstract
Our growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has opened new avenues for developing targeted therapies. These advances in treatment options targeting different mechanisms of action offer new hope for personalized management. In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). We also provide an update on the current status in clinical development of these new classes of therapeutics.
| Original language | English |
|---|---|
| Journal | Trends in Pharmacological Sciences |
| Volume | 38 |
| Issue number | 2 |
| Pages (from-to) | 127-142 |
| Number of pages | 16 |
| ISSN | 0165-6147 |
| DOIs | |
| Publication status | Published - 1 Feb 2017 |